90 related articles for article (PubMed ID: 15562384)
41. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Rosak C; Hofmann U; Paulwitz O
Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
[TBL] [Abstract][Full Text] [Related]
42. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
43. Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.
Carey PE; Gerrard J; Cline GW; Dalla Man C; English PT; Firbank MJ; Cobelli C; Taylor R
Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E941-7. PubMed ID: 15998660
[TBL] [Abstract][Full Text] [Related]
44. PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus.
Song JF; Wang T; Zhu J; Zhou XY; Lu Q; Guo H; Zhang F; Wang Y; Li W; Wang DD; Cui YW; Lv DM; Yin XX
Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):27-32. PubMed ID: 25311380
[TBL] [Abstract][Full Text] [Related]
45. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
Owens D
J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
[No Abstract] [Full Text] [Related]
46. The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.
Emral R; Köseoğlulari O; Tonyukuk V; Uysal AR; Kamel N; Corapçioğlu D
Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):80-4. PubMed ID: 15772898
[TBL] [Abstract][Full Text] [Related]
47. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
Shapiro MS; Abrams Z; Lieberman N
Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
[TBL] [Abstract][Full Text] [Related]
48. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure.
Chazan AC; Gomes MB
Braz J Med Biol Res; 2001 Jan; 34(1):49-56. PubMed ID: 11151028
[TBL] [Abstract][Full Text] [Related]
49. [Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)].
Scheen AJ
Rev Med Liege; 2001 Jun; 56(6):456-9. PubMed ID: 11496727
[TBL] [Abstract][Full Text] [Related]
50. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Landgraf R
Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
[TBL] [Abstract][Full Text] [Related]
51. Repaglinide for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
[No Abstract] [Full Text] [Related]
52. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Matthews DR; Boland O
Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
[TBL] [Abstract][Full Text] [Related]
53. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
Anwar A; Azmi KN; Hamidon BB; Khalid BA
Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
[TBL] [Abstract][Full Text] [Related]
54. Mechanisms of acute and chronic hypoglycemic action of gliclazide.
da Tos V; Maran A; Vigili de Kreutzenberg S; Marchetto S; Tadiotto F; Bettio M; Marescotti MC; Tiengo A; Del Prato S
Acta Diabetol; 2000; 37(4):201-6. PubMed ID: 11450504
[TBL] [Abstract][Full Text] [Related]
55. Development and validation of a new high-performance liquid chromatography method for the determination of gliclazide and repaglinide in pharmaceutical formulations.
Berecka A; Gumieniczek A; Hopkała H
J AOAC Int; 2006; 89(2):319-25. PubMed ID: 16640279
[TBL] [Abstract][Full Text] [Related]
56. Clinical Effects of Exercise Rehabilitation Combined with Repaglinide in the Treatment of Diabetes.
Li Y; Wang X; Zhang Y
Dis Markers; 2022; 2022():6309188. PubMed ID: 35371345
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.
Davis TM; Daly F; Walsh JP; Ilett KF; Beilby JP; Dusci LJ; Barrett PH
Br J Clin Pharmacol; 2000 Mar; 49(3):223-30. PubMed ID: 10718777
[TBL] [Abstract][Full Text] [Related]
58. New insights into metabolic and vascular management of type 2 diabetes. Proceedings of a meeting. Brussels, Belgium, September 1999.
J Diabetes Complications; 2000; 14(4):179-233. PubMed ID: 11004424
[No Abstract] [Full Text] [Related]
59. Subclinical type 1 diabetes.
Chowdhury TA; Lasker SS
J R Soc Med; 2002 Apr; 95(4):203-4. PubMed ID: 11934915
[No Abstract] [Full Text] [Related]
60. Differential metabolic network construction for personalized medicine: Study of type 2 diabetes mellitus patients' response to gliclazide-modified-release-treated.
Huang X; Zhou Y; Tang H; Liu B; Su B; Wang Q
J Biomed Inform; 2021 Jun; 118():103796. PubMed ID: 33932596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
